Velmanase alfa
| Clinical data | |
|---|---|
| Trade names | Lamzede |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| DrugBank | |
| UNII | |
| KEGG | |
Velmanase alfa, sold under the brand name Lamzede, is a medication for the treatment of alpha-mannosidosis.[1]
Velmanase alfa is a recombinant form of human alpha-mannosidase.[2]
Velmanase alfa was approved for medical use in the European Union in March 2018.[1][2]
References[]
- ^ a b c "Lamzede EPAR". European Medicines Agency (EMA). Retrieved 25 August 2020.
- ^ a b "Chiesi Group receives the European Marketing Authorisation for Lamzede" (Press release). 4 April 2018. Retrieved 24 August 2020.
External links[]
- "Velmanase Alfa". Drug Information Portal. U.S. National Library of Medicine.
- alpha-Mannosidase at the US National Library of Medicine Medical Subject Headings (MeSH)
 | This pharmacology-related article is a stub. You can help Wikipedia by . |
Categories:
- Orphan drugs
- Pharmacology stubs